Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells

There is an increasing interest in the development of Receptor Tyrosine Kinases inhibitors (RTKIs) for cancer treatment, as dysregulation of RTK expression can govern oncogenesis. Among the newer generations of RTKIs, many target Mer Tyrosine Kinase (MERTK) and Fms related RTK 3 (FLT3). Next to bein...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Richard M. Powell, Marlies J. W. Peeters, Anne Rahbech, Pia Aehnlich, Tina Seremet, Per thor Straten
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/ea4b29a1d4364e7390284cee2fd8917d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ea4b29a1d4364e7390284cee2fd8917d
record_format dspace
spelling oai:doaj.org-article:ea4b29a1d4364e7390284cee2fd8917d2021-11-25T19:11:00ZSmall Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells10.3390/vaccines91112942076-393Xhttps://doaj.org/article/ea4b29a1d4364e7390284cee2fd8917d2021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1294https://doaj.org/toc/2076-393XThere is an increasing interest in the development of Receptor Tyrosine Kinases inhibitors (RTKIs) for cancer treatment, as dysregulation of RTK expression can govern oncogenesis. Among the newer generations of RTKIs, many target Mer Tyrosine Kinase (MERTK) and Fms related RTK 3 (FLT3). Next to being overexpressed in many cancers, MERTK and FLT3 have important roles in immune cell development and function. In this study, we address how the new generation and potent RTKIs of MERTK/FLT3 affect human primary CD8<sup>+</sup> T cell function. Using ex vivo T cell receptor (TCR)-activated CD8<sup>+</sup> T cells, we demonstrate that use of dual MERTK/FLT3 inhibitor UNC2025 restricts CD8<sup>+</sup> T proliferation at the G2 phase, at least in part by modulation of mTOR signaling. Cytokine production and activation remain largely unaffected. Finally, we show that activated CD8<sup>+</sup> T cells express FLT3 from day two post activation, and FLT3 inhibition with AC220 (quizartinib) or siRNA-mediated knockdown affects cell cycle kinetics. These results signify that caution is needed when using potent RTKIs in the context of antitumor immune responses.Richard M. PowellMarlies J. W. PeetersAnne RahbechPia AehnlichTina SeremetPer thor StratenMDPI AGarticleMERTKFLT3CD8<sup>+</sup> T cellsT lymphocytesreceptor tyrosine kinasessmall molecule inhibitorsMedicineRENVaccines, Vol 9, Iss 1294, p 1294 (2021)
institution DOAJ
collection DOAJ
language EN
topic MERTK
FLT3
CD8<sup>+</sup> T cells
T lymphocytes
receptor tyrosine kinases
small molecule inhibitors
Medicine
R
spellingShingle MERTK
FLT3
CD8<sup>+</sup> T cells
T lymphocytes
receptor tyrosine kinases
small molecule inhibitors
Medicine
R
Richard M. Powell
Marlies J. W. Peeters
Anne Rahbech
Pia Aehnlich
Tina Seremet
Per thor Straten
Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
description There is an increasing interest in the development of Receptor Tyrosine Kinases inhibitors (RTKIs) for cancer treatment, as dysregulation of RTK expression can govern oncogenesis. Among the newer generations of RTKIs, many target Mer Tyrosine Kinase (MERTK) and Fms related RTK 3 (FLT3). Next to being overexpressed in many cancers, MERTK and FLT3 have important roles in immune cell development and function. In this study, we address how the new generation and potent RTKIs of MERTK/FLT3 affect human primary CD8<sup>+</sup> T cell function. Using ex vivo T cell receptor (TCR)-activated CD8<sup>+</sup> T cells, we demonstrate that use of dual MERTK/FLT3 inhibitor UNC2025 restricts CD8<sup>+</sup> T proliferation at the G2 phase, at least in part by modulation of mTOR signaling. Cytokine production and activation remain largely unaffected. Finally, we show that activated CD8<sup>+</sup> T cells express FLT3 from day two post activation, and FLT3 inhibition with AC220 (quizartinib) or siRNA-mediated knockdown affects cell cycle kinetics. These results signify that caution is needed when using potent RTKIs in the context of antitumor immune responses.
format article
author Richard M. Powell
Marlies J. W. Peeters
Anne Rahbech
Pia Aehnlich
Tina Seremet
Per thor Straten
author_facet Richard M. Powell
Marlies J. W. Peeters
Anne Rahbech
Pia Aehnlich
Tina Seremet
Per thor Straten
author_sort Richard M. Powell
title Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
title_short Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
title_full Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
title_fullStr Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
title_full_unstemmed Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
title_sort small molecule inhibitors of mertk and flt3 induce cell cycle arrest in human cd8<sup>+</sup> t cells
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/ea4b29a1d4364e7390284cee2fd8917d
work_keys_str_mv AT richardmpowell smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
AT marliesjwpeeters smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
AT annerahbech smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
AT piaaehnlich smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
AT tinaseremet smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
AT perthorstraten smallmoleculeinhibitorsofmertkandflt3inducecellcyclearrestinhumancd8supsuptcells
_version_ 1718410252009865216